The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
Open accessAbstract
High-throughput DNA sequencing significantly contributed to diagnosis and prognostication in patients with myelodysplastic syndromes (MDS). We determined the biological and prognostic significance of genetic aberrations in MDS. In total, 944 patients with various MDS subtypes were screened for known/putative mutations/deletions in 104 genes using targeted deep sequencing and array-based genomic hybridization. In total, 845/944 patients (89.5%) harbored at least one mutation (median, 3 per patient; range, 0-12). Forty-seven genes were significantly mutated with TET2, SF3B1, ASXL1, SRSF2, DNMT3A, and RUNX1 mutated in >10% of cases. Many mutations were associated with higher risk groups and/or blast elevation. Survival was investigated in 875 patients. By univariate analysis, 25/48 genes (resulting from 47 genes tested significantly plus PRPF8) affected survival (P<0.05). The status of 14 genes combined with conventional factors revealed a novel prognostic model ('Model-1') separating patients into four risk groups ('low', 'intermediate', 'high', 'very high risk') with 3-year survival of 95.2, 69.3, 32.8, and 5.3% (P<0.001). Subsequently, a 'gene-only model' ('Model-2') was constructed based on 14 genes also yielding four significant risk groups (P<0.001). Both models were reproducible in the validation cohort (n=175 patients; P<0.001 each). Thus, large-scale genetic and molecular profiling of multiple target genes is invaluable for subclassification and prognostication in MDS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“dysregulated iron metabolism is a hallmark of a large subset of MDS with ringed sideroblasts (MDS-RS), characterized by aberrant iron accumulation in erythroblast mitochondria and accounting for ~30% of all MDS cases (42).”
From Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction (2022) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TP53 gene mutations are detected in approximately 10%-20% of patients with de novo myelodysplastic syndromes (MDS)1-4 or acute myeloid leukemia (AML)5,6 and 30%-40% of patients with therapy-related disease.7”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the context of MDS, eprenetapopt is currently only indicated in ~7% of all MDS cases (42).”
From Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction (2022) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Splicing factor mutations are common in AMl and other blood malignancies and are often mutually exclusive (Haferlach et al. 2014;Papaemmanuil et al. 2016), indicating that cancers harboring such mutations may rely on an intact splicing machinery for survival (lee et al. 2018).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Haferlach et al. 2014
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Regression shrinkage and selection via the lasso
Tibshirani, R. (1996) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1996.tb02080.x · Cited by 51,482
Sequencing technologies – the next generation
Metzker, M. L. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2626 · Cited by 7,066
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 3,224
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
Self-citationDNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C. J., Ellis, P., Wedge, D. C., Pellagatti, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-518886 · Cited by 1,832
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Several Tests for Model Specification in the Presence of Alternative Hypotheses
Davidson, R., & MacKinnon, J. G. (1981) · Econometrica · doi:10.2307/1911522 · Cited by 1,747
Flagged first, then by citations
Research works printed but not linked: 1
- Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman J et al. Myelodysplastic syndromes. In: Jaffe ES, Harris N, Stein H, Vardiman J, eds World Health Organization of Tumors, Pathology & Genetics, Tumors of haematopoietic and lymphoid tissues. IARC Press: Lyon, France, 2001; pp 61–73.
Cited by
Sorted by citations
Items 501–600 of 999
Awada, H. K., Thapa, B., & Visconte, V. (2020) · Cells · doi:10.3390/cells9112512 · Cited by 26
Diesch, J., Pannérer, M.-M. L., Winkler, R., Casquero, R., Muhar, M., van der Garde, M., Maher, M., Herraez, C. M., Bech‐Serra, J. J., Fellner, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26258-z · Cited by 25
Epigenetic Changes as a Target in Aging Haematopoietic Stem Cells and Age-Related Malignancies
Buisman, S. C., & de Haan, G. (2019) · Cells · doi:10.3390/cells8080868 · Cited by 24
Ravindran, A., He, R. L., Ketterling, R. P., Jawad, M. D., Chen, D., Oliveira, J. L., Nguyen, P. L., Viswanatha, D. S., Reichard, K. K., Hoyer, J. D., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0275-8 · Cited by 24
Summerer, I., Haferlach, C., Meggendorfer, M., Kern, W., Haferlach, T., & Stengel, A. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1737689 · Cited by 25
Self-citationWang, H., Guo, Y., Dong, Z., Li, T., Xie, X., Wan, D., Jiang, Z., Yu, J., & Guo, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-74744-z · Cited by 24
Genetics of Myelodysplastic Syndromes
Saygin, C., & Godley, L. A. (2021) · Cancers · doi:10.3390/cancers13143380 · Cited by 24
Updates in molecular genetics of acute myeloid leukemia
Kurzer, J. H., & Weinberg, O. K. (2023) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2023.04.002 · Cited by 28
The molecular basis of myeloid malignancies
Kitamura, T., Inoue, D., Okochi, N., Kato, N., Komeno, Y., Yang, L. U., Enomoto, Y., Doki, N., UCHIDA, T., Kagiyama, Y., et al. (2014) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.90.389 · Cited by 26
Dimitriou, M., Woll, P. S., Blanco, T. M., Karimi, M., Wedge, D. C., Doolittle, H., Douagi, I., Papaemmanuil, E., Jacobsen, S. E. W., & Hellström‐Lindberg, E. (2016) · Oncotarget · doi:10.18632/oncotarget.12234 · Cited by 23
Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis
Neukirchen, J., Lauseker, M., Hildebrandt, B., Nolting, A., Kaivers, J., Kobbe, G., Gattermann, N., Haas, R. R., & Germing, U. (2017) · Cancer · doi:10.1002/cncr.30917 · Cited by 24
Myelodysplastic syndrome patient-derived xenografts: from no options to many
Côme, C., Balhuizen, A., Bonnet, D. A., & Porse, B. T. (2020) · Haematologica · doi:10.3324/haematol.2019.233320 · Cited by 24
TET2 expression level and 5-hydroxymethylcytosine are decreased in refractory cytopenia of childhood
Coutinho, D. F., Monte-Mór, B. D. C. R., Vianna, D. T., Rouxinol, S. T., Batalha, A. B. W., Bueno, A. P. S., de Azevedo, A. M. B., Fernandez, T. D. S., Pombo‐de‐Oliveira, M. S., Gutiyama, L. M., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.07.005 · Cited by 24
Diagnostics and Prognostication of Myelodysplastic Syndromes
Zini, G. (2017) · Annals of Laboratory Medicine · doi:10.3343/alm.2017.37.6.465 · Cited by 25
Hoermann, G., Greiner, G., Griesmacher, A., & Valent, P. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030094 · Cited by 23
Murine Models of Myelofibrosis
Jacquelin, S., Kramer, F., Mullally, A., & Lane, S. (2020) · Cancers · doi:10.3390/cancers12092381 · Cited by 26
A cohesive look at leukemogenesis: The cohesin complex and other driving mutations in AML
Heimbruch, K. E., Meyer, A. E., Agrawal, P., Viny, A. D., & Rao, S. (2021) · Neoplasia · doi:10.1016/j.neo.2021.01.003 · Cited by 23
Huber, S., Haferlach, T., Meggendorfer, M., Hütter, S., Hoermann, G., Baer, C. R., Kern, W., & Haferlach, C. (2022) · Leukemia · doi:10.1038/s41375-022-01734-7 · Cited by 23
Self-citationDiscovery of U2AF1 neoantigens in myeloid neoplasms
Biernacki, M. A., Lok, J., Black, R. G., Foster, K. A., Cummings, C. C., Woodward, K. B., Monahan, T. M., Oehler, V. G., Stirewalt, D. L., Wu, D., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007490 · Cited by 24
Cutting the cord from myelodysplastic syndromes
Padron, E., & Steensma, D. P. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000112 · Cited by 24
Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization
He, R. L., Wiktor, A. E., Durnick, D. K., Kurtin, P. J., Dyke, D. L. V., Tefferi, A., Patnaik, M. M., Ketterling, R. P., & Hanson, C. A. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw077 · Cited by 24
Suzuki, Y., Tomita, A., Nakamura, F., Iriyama, C., Shirahata‐Adachi, M., Shimada, K., Akashi, A., Ishikawa, Y., Kaneda, N., & Kiyoi, H. (2016) · Cancer Science · doi:10.1111/cas.12994 · Cited by 23
Targeting TP53 Mutations in Myelodysplastic Syndromes
Hunter, A. M., & Sallman, D. A. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.11.004 · Cited by 25
Amorós-Pérez, M., & Fuster, J. J. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.02.008 · Cited by 24
Caprioli, C., Lussana, F., Salmoiraghi, S., Cavagna, R., Buklijas, K., Elidi, L., Zanghì, P., Michelato, A., Delaini, F., Oldani, E., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.252825 · Cited by 23
Zhang, J., Xie, J., Huang, J. W., Liu, X., Xu, R., Tholen, J., Galej, W. P., Tong, L., Manley, J. L., & Liu, Z. (2023) · Genes & Development · doi:10.1101/gad.351154.123 · Cited by 25
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations
Shah, M. V., Hung, K., Baranwal, A., Kutyna, M. M., Al-Kali, A., Toop, C., Greipp, P., Brown, A., Shah, S., Khanna, S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015238 · Cited by 23
Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs
Thoms, J. A. I., Yan, F., Hampton, H. R., Davidson, S., Joshi, S. M., Saw, J., Sarowar, C. H., Lim, X. Y., Nunez, A. C., Kakadia, P. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59796-x · Cited by 25
Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes
Madan, V., Li, J., Zhou, S., Teoh, W. W., Han, L., Meggendorfer, M., Malcovati, L., Cazzola, M., Ogawa, S., Haferlach, T., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25673 · Cited by 22
Self-citationCurrent concepts and future directions for hemato-oncologic diagnostics
Flach, J., Shumilov, E., Joncourt, R., Porret, N. A., Novak, U., Pabst, T., & Bacher, U. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102977 · Cited by 24
Self-citationHuang, L., Liu, Z., Liu, H., Ding, K., Mi, F., Xiang, C., Wang, G., Guo, Y., & Fu, R. (2020) · Stem Cells International · doi:10.1155/2020/8855038 · Cited by 22
Bernardi, S., & Farina, M. (2021) · Biology · doi:10.3390/biology10020105 · Cited by 23
Mian, S. A., & Bonnet, D. A. (2021) · Cancers · doi:10.3390/cancers13164116 · Cited by 22
Impaired formation of neutrophil extracellular traps in patients with MDS
Brings, C., Fröbel, J., Cadeddu, R., Germing, U., Haas, R. R., & Gattermann, N. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005721 · Cited by 22
Menssen, A. J., Khanna, A., Miller, C. A., Srivatsan, S. N., Chang, G. S., Shao, J., Robinson, J., O’Laughlin, M., Fronick, C. C., Fulton, R. S., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0155 · Cited by 23
Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation
Rodríguez‐Sevilla, J. J., Ademà, V., Garcia‐Manero, G., & Colla, S. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100940 · Cited by 23
Wong, J. J. L., Lau, K. A., Pinello, N., & Rasko, J. E. J. (2014) · Cancer Science · doi:10.1111/cas.12532 · Cited by 23
Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions
Chamseddine, A. N., Jabbour, E. J., Kantarjian, H. M., Bohannan, Z. S., & Garcia‐Manero, G. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0489-2 · Cited by 22
Molecular features of early onset adult myelodysplastic syndrome
Hirsch, C. M., Przychodzen, B. P., Radivoyevitch, T., Patel, B. J., Thota, S., Clemente, M. J., Nagata, Y., LaFramboise, T., Carraway, H. E., Nazha, A., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.159772 · Cited by 22
Self-citationKim, S. Y., Park, Y., Kim, H., Kim, J., Kwon, G. C., & Koo, S. H. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.029 · Cited by 22
Drevon, L., Marceau‐Renaut, A., Maarek, O., Cuccuini, W., Clappier, E., Éclache, V., Cluzeau, T., Richez, V., Berkaoui, I., Dimicoli, S., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15490 · Cited by 22
Abuhadra, N. K., Mukherjee, S., Al-Issa, K., Ademà, V., Hirsch, C. M., Advani, A. S., Przychodzen, B. P., Makhoul, A., Awada, H. K., Maciejewski, J. P., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1543885 · Cited by 22
Shanmugam, V., Parnes, A. D., Kalyanaraman, R., Morgan, E. A., & Kim, A. S. (2019) · Blood · doi:10.1182/blood.2019001610 · Cited by 22
Martín‐Izquierdo, M., Abáigar, M., Hernández-Sánchez, J. M., Tamborero, D., Cadenas, F. L., Ramos, F., Lumbreras, E., Madinaveitia-Ochoa, A., Megido, M., Labrador, J., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.248807 · Cited by 22
A microglia clonal inflammatory disorder in Alzheimer’s disease
Vicario, R., Fragkogianni, S., Weber, L., Lazarov, T., Hu, Y., Hayashi, S. Y., Craddock, B., Socci, N. D., Alberdi, A., Baako, A., et al. (2025) · eLife · doi:10.7554/elife.96519.3 · Cited by 21
Nazha, A., Sekeres, M. A., Gore, S. D., & Zeidan, A. M. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0067 · Cited by 22
Somatic Mutations in Aplastic Anemia
Mufti, G. J., & Marsh, J. C. W. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.03.002 · Cited by 21
Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice
Lee, J., Godfrey, A. L., & Nangalia, J. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100708 · Cited by 21
Role of the HOXA cluster in HSC emergence and blood cancer
Abuhantash, M. A., Collins, E. M., & Thompson, A. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210234 · Cited by 21
Allogeneic stem cell transplantation for patients with myelodysplastic syndromes
Vittayawacharin, P., Kongtim, P., & Ciurea, S. O. (2022) · American Journal of Hematology · doi:10.1002/ajh.26763 · Cited by 23
The genetics of myelodysplastic syndromes and the opportunities for tailored treatments
Kontandreopoulou, C., Kalopisis, K., Viniou, N., & Diamantopoulos, P. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.989483 · Cited by 23
Epigenetic regulation by ASXL1 in myeloid malignancies
Yang, F., & Agosto-Peña, J. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03586-y · Cited by 22
Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells
Im, H., Rao, V., Sridhar, K. J., Bentley, J., Mishra, T., Chen, R., Hall, J., Graber, A., Zhang, Y., Li, X., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1452210 · Cited by 22
Biamonti, G., Maita, L., & Montecucco, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00408 · Cited by 22
Montes, P., Kerick, M., Bernal, M., Hernandez, F. M., Jiménez, P., Garrido, P., Márquez, A., Jurado, M., Martin, J. J., Garrido, F., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26405 · Cited by 21
The evolving role of next generation sequencing in myelodysplastic syndromes
Spaulding, T. P., Stockton, S. S., & Savona, M. R. (2019) · British Journal of Haematology · doi:10.1111/bjh.16212 · Cited by 21
Cao, Y., Liu, Y., Shang, L., Wei, W., Shen, Y., Gu, Q., Xie, X., Dong, W., Lin, Y., Yue, Y., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109878 · Cited by 21
Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status
Shrestha, R., Sakata‐Yanagimoto, M., Maie, K., Oshima, M., Ishihara, M., Suehara, Y., Fukumoto, K., Nakajima‐Takagi, Y., Matsui, H., Kato, T., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001324 · Cited by 22
Self-citationAutomated leukocyte parameters are useful in the assessment of myelodysplastic syndromes
Shestakova, A., Nael, A., Nora, V., Rezk, S. A., & Zhao, X. (2020) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21947 · Cited by 21
Kaito, S., & Iwama, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010074 · Cited by 21
Metzeler, K. H., & Bloomfield, C. D. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_12 · Cited by 22
Combined landscape of single-nucleotide variants and copy-number alterations in clonal hematopoiesisPreprint
Saiki, R., Momozawa, Y., Nannya, Y., Nakagawa, M. M., Ochi, Y., Yoshizato, T., Terao, C., Kuroda, Y., Shiraishi, Y., Chiba, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.05.433727 · Cited by 22
Self-citationThe current perspective of low-grade myelodysplastic syndrome in children
Hasegawa, D. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-1965-7 · Cited by 21
New challenges in evaluating anemia in older persons in the era of molecular testing
Steensma, D. P. (2016) · Hematology · doi:10.1182/asheducation-2016.1.67 · Cited by 20
MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells
Pollyea, D. A., Kim, H. M., Stevens, B. M., Lee, F. F.-Y., Harris, C., Hedin, B. R., Knapp, J. R., O’Connor, B. P., Jordan, C. T., Pietras, E. M., et al. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.6ab0520-318rr · Cited by 20
SF3B1 mutant myelodysplastic syndrome: Recent advances
Pellagatti, A., & Boultwood, J. (2020) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100776 · Cited by 20
Bewersdorf, J. P., & Zeidan, A. M. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101245 · Cited by 18
Fattizzo, B., Levati, G. V., Giannotta, J. A., Cassanello, G., Cro, L., Zaninoni, A., Barbieri, M., Croci, G. A., Revelli, N., & Barcellini, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.795955 · Cited by 21
Comprehensive analysis of genetic factors predicting overall survival in Myelodysplastic syndromes
Maurya, N., Mohanty, P., Dhangar, S., Panchal, P., Jijina, F. F., Mathan, S. L. P., Shanmukhaiah, C., Madkaikar, M. R., & Vundinti, B. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-09864-9 · Cited by 22
Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS
Velegraki, M., Stiff, A. R., Papadaki, H. Α., & Li, Z. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164908 · Cited by 20
Bewersdorf, J. P., Xie, Z., Bejar, R. L., Borate, U., Boultwood, J., Brunner, A. M., Buckstein, R. J., Carraway, H. E., Churpek, J. E., Daver, N. G., et al. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101072 · Cited by 22
Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms
Brierley, C. K., & Steensma, D. P. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0344-z · Cited by 20
Splicing factor mutations in MDS RARS and MDS/MPN-RS-T
Yoshimi, A., & Abdel-Wahab, O. I. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2242-0 · Cited by 20
Cull, A. H., Mahendru, D., Snetsinger, B., Good, D. J., Tyryshkin, K., Chesney, A. E., Ghorab, Z., Reis, M. D., Buckstein, R. J., Wells, R. A., et al. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.12.003 · Cited by 20
Tang, Y., Miao, M., Han, S., Qi, J., Wang, H., Ruan, C., Wu, D., & Han, Y. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.013 · Cited by 19
The MDS genomics-prognosis symbiosis
Nazha, A. (2018) · Hematology · doi:10.1182/asheducation-2018.1.270 · Cited by 20
Bødker, J. S., Sønderkær, M., Vesteghem, C., Schmitz, A., Brøndum, R. F., Sommer, M., Rytter, A. S., Nielsen, M. M., Madsen, J., Jensen, P., et al. (2020) · Cancers · doi:10.3390/cancers12020312 · Cited by 20
Wang, K., Zhou, F., Cai, X., Chao, H., Zhang, R., & Chen, S. (2020) · Hematology · doi:10.1080/16078454.2020.1765561 · Cited by 20
Chen, X., Fromm, J. R., & Naresh, K. N. (2022) · Leukemia · doi:10.1038/s41375-021-01498-6 · Cited by 20
Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype
Ahn, J., Kim, H., Kim, Y., Lee, S.-S., Ahn, S., Jung, S., Yang, D., Lee, J., Park, H. J., Lee, J.-Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23575 · Cited by 20
Application of genome editing technologies to the study and treatment of hematological disease
Pellagatti, A., Dolatshad, H., Yip, B. H., Valletta, S., & Boultwood, J. (2015) · Advances in Biological Regulation · doi:10.1016/j.jbior.2015.09.005 · Cited by 20
Kawabata, H., Tohyama, K., Matsuda, A., Araseki, K., Hata, T., Suzuki, T., Kayano, H., Shimbo, K., Zaike, Y., Usuki, K., et al. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2250-0 · Cited by 19
Badat, I., Mirza, S., Padron, E., Sallman, D. A., Komrokji, R. S., Song, J., & Hussaini, M. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2019-206132 · Cited by 19
Evolving therapies for lower-risk myelodysplastic syndromes
Bewersdorf, J. P., & Zeidan, A. M. (2020) · Annals of Hematology · doi:10.1007/s00277-020-03963-1 · Cited by 19
Madan, V., Cao, Z., Teoh, W. W., Dakle, P., Han, L., Shyamsunder, P., Jeitany, M., Zhou, S., Li, J., Nordin, H. B. M., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.260562 · Cited by 19
Self-citationMyelodysplasia Syndrome, Clonal Hematopoiesis and Cardiovascular Disease
Veiga, C. B., Lawrence, E., Murphy, A. J., Herold, M. J., & Dragoljevic, D. (2021) · Cancers · doi:10.3390/cancers13081968 · Cited by 20
Pellagatti, A., & Boultwood, J. (2022) · Advances in Biological Regulation · doi:10.1016/j.jbior.2022.100920 · Cited by 19
Lee, E.-J., & Zeidan, A. M. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1016905 · Cited by 19
A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia
Sakai, H., Hosono, N., Nakazawa, H., Przychodzen, B. P., Polprasert, C., Carraway, H. E., Sekeres, M. A., Radivoyevitch, T., Yoshida, K., Sanada, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.319 · Cited by 19
Self-citationCD177 Enhances the Detection of Myelodysplastic Syndrome by Flow Cytometry
Alayed, K. M., Meyerson, J. B., Osei, E. S., Blidaru, G., Schlegelmilch, J., Johnson, M. L., & Meyerson, H. J. (2019) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqz196 · Cited by 19
Asimomitis, G., Deslauriers, A. G., Kotini, A. G., Bernard, E., Esposito, D., Olszewska, M., Spyrou, N., Ossa, J. A., Blanco, T. M., Koche, R. P., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006325 · Cited by 18
Self-citationUnique role of DDX41, a DEAD-box type RNA helicase, in hematopoiesis and leukemogenesis
Shinriki, S., & Matsui, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.992340 · Cited by 19
Biomarkers in Hematological Malignancies: A Review of Molecular Testing in Hematopathology
Hussaini, M. (2015) · Cancer Control · doi:10.1177/107327481502200206 · Cited by 20
Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia
Woll, P. S., Yoshizato, T., Hellström‐Lindberg, E., Fioretos, T., Ebert, B. L., & Jacobsen, S. E. W. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13535 · Cited by 15
Role of functional genomics in identifying cancer drug resistance and overcoming cancer relapse
Mahgoub, E. O., Cho, W. C. S., Sharifi, M., Falahati, M., Zeinabad, H. A., Mare, H. E., & Hasan, A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22095 · Cited by 20
MDS Is a Stem Cell Disorder After All
Jaiswal, S., & Ebert, B. L. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.001 · Cited by 18
Karimi, M., Nilsson, C. C., Dimitriou, M., Jansson, M., Matsson, H., Unneberg, P., Lehmann, S., Kere, J., & Hellström‐Lindberg, E. (2015) · Haematologica · doi:10.3324/haematol.2014.118034 · Cited by 17
Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Nardi, V., & Hasserjian, R. P. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2015.10.004 · Cited by 19
Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?
Dezern, A. E. (2015) · Hematology · doi:10.1182/asheducation-2015.1.308 · Cited by 18
Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
Clara, J., Clara, J., Sallman, D. A., Padron, E., Sallman, D. A., & Padron, E. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0043 · Cited by 18
Metadata
- Authors
- Haferlach, T., Nagata, Y., Grossmann, V, Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., Yoshida, K., Roller, A., Nadarajah, N., Shiraishi, Y., Shiozawa, Y., Chiba, K., Tanaka, H., Koeffler, H. P., Klein, H.-U., Dugas, M., Aburatani, H., Kohlmann, A., Miyano, S., Haferlach, C., Kern, W., & Ogawa, S.
- Affiliations
- Munich Leukemia Laboratory (Germany) (DE)
- Kyoto University (JP)
- The University of Tokyo (JP)
- Research Center for Advanced Science and Technology, The University of Tokyo (JP)
- Institute of Medical Science, The University of Tokyo (JP)
- Cedars-Sinai Medical Center (US)
- University of Münster (DE)
- Corresponding author
- Haferlach, T
- Ogawa, S
- ORCID
- Venue
- Leukemia
- Published
- 2013-11-13
- Volume
- 28
- Issue
- 2
- Pages
- 241-247
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- PMC
- PMC3918868
- OpenAlex
- W2026134786
- Cited by
- 1,532
- References
- 32
- Citations by year
- 2026: 56 · 2025: 85 · 2024: 102 · 2023: 132 · 2022: 133 · 2021: 177 · 2020: 167 · 2019: 134 · 2018: 117 · 2017: 136 · 2016: 126 · 2015: 105 · 2014: 56 · 2013: 3
- FWCI
- 69.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- Leukemia (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- Funders
- U.S. Public Health Service (08C46598A)
- Japan Society for the Promotion of Science (24390242, 24659458, 21790907, 25670446, 24221011, 23249052)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- myelodysplastic syndrome, somatic mutations, prognostic model, risk stratification, TET2, SF3B1, ASXL1, SRSF2, DNMT3A, RUNX1, PRPF8, survival
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Gene Frequency, Genetic Markers, Humans, Male, Middle Aged, Mutation, Myelodysplastic Syndromes, Prognosis, Proportional Hazards Models, Polymorphism, Single Nucleotide, Young Adult, Genetic Association Studies, High-Throughput Nucleotide Sequencing, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
